Search

Methyclothiazide

(From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

Eflapegrastim

in which the patient develops an infection during a period of significant neutropenia. … chemotherapy-induced neutropenia, including FN.

Primidone

[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.

Motixafortide

[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within

Imidacloprid

It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide.

Agomelatine

Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.

Firuglipel

Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin). … Firuglipel has a monoisotopic molecular weight of 467.19 Da.

Lerodalcibep

[L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia … [L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels.

Elivaldogene autotemcel

[L40298] In September 2022, Skysona was approved by the FDA.[L43247] … It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.

Hexamidine